Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials

This study used data from The Safety, Tolerability, and Efficacy Assessment of Isradipine for Parkinson Disease (STEADY-PD III; NCT02168842) and the Study of Urate Elevation in Parkinson’s Disease (SURE-PD3; NCT02642393).

Source: Neurology Clinical Practice - January 18, 2023 Category: Neurology Authors: Di Luca, D. G., Macklin, E. A., Hodgeman, K., Lopez, G., Pothier, L., Callahan, K. F., Lowell, J., Chan, J., Videnovic, A., Lungu, C., Lang, A. E., Litvan, I., Schwarzschild, M. A., Simuni, T. Tags: Parkinson's disease/Parkinsonism, Clinical trials Methodology/study design, Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS), Health disparities, Structural and social determinants of health RESEARCH ARTICLE Source Type: research